Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24272787&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 261.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24272787.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Cachexia+Sarcopenia+Muscle 2014 ; 5 (2): 149-58 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats #MMPMID24272787
Pötsch MS; Tschirner A; Palus S; von Haehling S; Doehner W; Beadle J; Coats AJS; Anker SD; Springer J
J Cachexia Sarcopenia Muscle 2014[Jun]; 5 (2): 149-58 PMID24272787show ga
Background: Sarcopenia, the age-related, progressive loss of skeletal muscle mass, strength, and function, is a considerable socioeconomic burden by increasing risks of falls, fractures, and frailty. Moreover, sarcopenic patients are often obese and therapeutic options are very limited. Methods: Here, we assessed the efficacy of espindolol on muscle mass in 19-month-old male Wistar Han rats (weight, 555?±?18 g), including safety issues. Rats were randomized to treatment with 3 mg/kg/day espindolol (n?=?8) or placebo (n?=?14) for 31 days. Results: Placebo-treated rats progressively lost body weight (?15.5?±?7.2 g), lean mass (?1.5?±?4.2 g), and fat mass (?15.6?±?2.7 g), while espindolol treatment increased body weight (+8.0?±?6.1 g, p?0.05), particularly lean mass (+43.4?±?3.5 g, p?0.001), and reduced fat mass further (?38.6?±?3.4 g, p?0.001). Anabolic/catabolic signaling was assessed in gastrocnemius muscle. Espindolol decreased proteasome and caspase-3 proteolytic activities by approximately 50 % (all p?0.05). Western blotting showed a reduced expression of key catabolic regulators, including NF?B, MuRF1, and LC-3 (all p?0.01). The 50- and 26-kDa forms of myostatin were downregulated fivefold and 20-fold, respectively (both p?0.001). Moreover, 4E-BP-1 was reduced fivefold (p?0.01), while phospho-PI3K was upregulated fivefold (p?0.001), although Akt expression and phosphorylation were lower compared to placebo (all p?0.05). No regulation of p38 and expression of ERK1/2 were observed, while phosphorylation of p38 was reduced (?54 %, p?0.001) and ERK1/2 was increased (115 and 83 %, respectively, both p?0.01). Espindolol did not affect cardiac function (echocardiography) or clinical plasma parameters. Conclusion: Espindolol reversed the effects of aging/sarcopenia, particularly loss of muscle mass and increased fat mass. Thus, espindolol is an attractive candidate drug for the treatment of sarcopenia patients. Electronic supplementary material: The online version of this article (doi:10.1007/s13539-013-0125-7) contains supplementary material.